CTRI/2022/08/044867已完成未知
A Proof-of-Concept, Safety and Efficacy Study of SkinQ GlowBright Wonder Mask in Healthy Human Subjects and withadequate representation of varied skin types (Normal, Oily,Dry, Combined, and Sensitive skin).
Health Q Life Sciences Private Limited0 个研究点目标入组 38 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Age: 18 to 55 years (both inclusive) old at the time of consent.
- •2) Sex: Healthy adult males and non-pregnant/non-lactating females.
- •3) Subject with normal Fitzpatrick skin type III to VI (Human skin colour determination scale).
- •4) Females of childbearing potential must have a self-reported negative urine pregnancy test.
- •5) Subjects are generally in good general health as determined from recent medical history.
- •6) Subjects with visibly tanned skin determine by a dermatologist or dermatologist trained evaluator.
- •7) The subject does not have any previous history of adverse skin conditions and is not under any medication likely to interfere with the results.
- •8) The subjects who have not done any facial treatment, or any herbal facial, tanning removal for more than 30 days and who regularly use tanning removal products.
- •9) The subject is willing and able to follow the study directions, and participate in the study.
- •10)The subject must be able to understand and provide written informed consent to participate in the study.
排除标准
- •1) Subject with known allergy or sensitization to product ingredients such as niacinamide, glycolic acid, Liquorice, vitamin c, mulberries, purple brazilian clay or any other ingredients.
- •2) The subject had a facial or chemical peeling or derma abrasion | roller etc. in the last 4 weeks.
- •3) The subject has skin irritation, open wounds, cuts, abrasions, irritation symptoms or any dermatological condition on the face that can interfere with the reading.
- •4) Be wearing any facial makeup, including false eyelashes, on the day of the study visit.
- •5) Be using any skin lightening | brightening or tanning removal product within 15 days and on the day of the study visit.
- •6) Medication which may affect skin response and/or past medical history.
- •7) The subject has a history of diabetes
- •8) The subject has a history of mastectomy for cancer involving removal of lymph nodes within the past year, or treatment of any type of cancer within the last 6 months.
- •9) The subject suffering from any active clinically significant skin diseases which may contraindicate.
- •10) The subject has a history of any skin diseases including eczema, atopic dermatitis etc.
- •11) Subject with self-reported immunological disorders such as HIV positive, AIDS and/or systemic lupus erythematosus.
- •12) Have taken antihistamines (including those in cold tablets, OTC allergy medications, decongestants and inhalants) or analgesics (including aspirin or other over-the-counter analgesics) on the days of the study.
- •13) An individual who has a medical condition or is taking or has taken a medication which, in the Investigatorââ?¬•s judgment, makes the subject ineligible or places the subject at undue risk.
- •14) Participation in other clinical studies simultaneously
研究者
相似试验
已完成
不适用
Exploratory study for the efficacy and safety of Sansoninto on behavioral and psychological symptoms of dementia (BPSD) in patients with Dementia.: Multicenter trialDementia patients with BPSDJPRN-UMIN000021562Kanazawa University20
已完成
不适用
Clinical Investigation of Efficacy and Safety in Second-line Bevacizumab treatment combined with FOLFIRI or FOLFOX for metastatic colorectal cancercolorectal cancerJPRN-UMIN000001547Tsukuba Cancer Clinical Trial Group400
已完成
2 期
The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment.Thyroid cancerJPRN-UMIN000017777niversity of Tsukuba47
已完成
不适用
A clinical study to assess the safety and effectiveness of Anti-Gray Hair Product in Healthy Adult Human Subjects with Partially Gray HairCTRI/2023/01/048861Anveya Living Private Limited84
尚未招募
不适用
A prospective study about efficacy and safety of selective arterial injection chemotherapy for ineffective or intorelable to the standard chemotherapy in advanced esophageal cancerEsophagusJPRN-UMIN000028542Showa University Koto Toyosu Hospital50